Skip to content
Dezocine
Dalgan (dezocine) is a small molecule pharmaceutical. Dezocine was first approved as Dalgan on 1989-12-29. It is used to treat pain in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
signs and symptoms pathological conditionsD013568
psychological phenomenaD011579
musculoskeletal and neural physiological phenomenaD055687
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Dezocine
Tradename
Company
Number
Date
Products
DALGANAstraZenecaN-019082 DISCN1989-12-29
3 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
painEFO_0003843D010146R52
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N02: Analgesics
— N02A: Opioid analgesics
— N02AX: Other opioids in atc
— N02AX03: Dezocine
HCPCS
No data
Clinical
Clinical Trials
164 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AnesthesiaD000758—1361019
General anesthesiaD000768111147
ObesityD009765EFO_0001073E66.9—1—315
DeliriumD003693R41.0———325
Postoperative cognitive complicationsD00007969011—225
Coronary artery bypassD001026EFO_0003776———123
Colorectal neoplasmsD015179—1—113
ArthritisD001168EFO_0005856M05-M14———2—2
Delayed emergence from anesthesiaD055191———112
Prostatic neoplasmsD011471C61———2—2
Show 38 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Postoperative painD010149G89.18—11—24
HepatectomyD0064981—1——2
Musculoskeletal diseasesD009140——1——1
CystoscopesD020684——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Postoperative nausea and vomitingD020250EFO_0004888—1——12
Replacement arthroplasty kneeD019645—1———1
Orthopedic proceduresD019637—1———1
Down syndromeD004314EFO_0001064Q90—1———1
Kidney transplantationD016030—1———1
Drug-related side effects and adverse reactionsD064420T88.7—1———1
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hip fracturesD006620EFO_0003964S72.00————22
Anesthesia recovery periodD000762————22
Inhalation anesthesiaD000769————22
Pituitary neoplasmsD010911————22
Dna damageD004249————22
HypotensionD007022EFO_0005251I95————11
RhytidoplastyD015361————11
Sleep wake disordersD012893G47————11
Animal mammary neoplasmsD015674————11
Enhanced recovery after surgeryD000080482————11
Show 40 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDEZOCINE
INNdezocine
Description
Dezocine is (7S,8S)-7-Amino-8-methyl-5,6,7,8-tetrahydronaphthalen-2-ol in which the hydrogen at position 8 and one of the hydrogens at position 6 are substituted by each end of a tetramethylene bridge. A synthetic opioid analgesic, it has mixed opiod agonist and antagonist properties. Although it is used for pain management, it can produce opioid withdrawal syndrome in patients already dependent on other opioids, and its clinical application is limited by side effects such as dizziness. It has a role as an opioid analgesic. It is a member of phenols and a primary amino compound.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
C[C@@]12CCCCC[C@@H](Cc3ccc(O)cc31)[C@@H]2N
Identifiers
PDB—
CAS-ID53648-55-8
RxCUI22713
ChEMBL IDCHEMBL1685
ChEBI ID4474
PubChem CID3033053
DrugBankDB01209
UNII IDVHX8K5SV4X (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 579 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1,071 adverse events reported
View more details